CRSP has taken a beating over the past few months, but they are still the leader in gene editing. It looks like we are starting to see a rotation of money back into genomics, which will play a crucial role in avoiding these pandemics in the future. CRSP has broken out of the wedge that it has been trading in and we are likely to see a 9/50 EMA cross over very soon. I love this company long.